Hawthorn Berry: A Century of Cardiovascular Use and What Trials Show

Used in European cardiology since the 1800s, with a modern trial record and some genuinely significant drug interactions.

A long history and a modern record

Hawthorn is unusual among cardiovascular botanicals in having both a long traditional record and a reasonable body of modern trial evidence. It has been used in European medicine for cardiac indications since the nineteenth century and remains a licensed herbal medicine for cardiac indications in several European countries.

That regulatory status matters more than tradition does. It means standardised preparations exist with defined constituent content, which is the exception rather than the rule in botanical supplementation.

What is in it and what it does

The active constituents are principally oligomeric procyanidins and flavonoids including vitexin and hyperoside. Leaf and flower preparations generally carry higher concentrations than berry alone, which is why quality extracts often specify leaf-and-flower.

The studied effects centre on three things: myocardial contractility, coronary blood flow, and vascular tone. Mechanistically, hawthorn has been examined for inhibition of phosphodiesterase and for effects on nitric oxide-mediated vasodilation, alongside antioxidant activity on vascular endothelium.

The overall picture from the literature is of modest positive inotropic effect combined with vasodilation — a combination that reduces cardiac workload while supporting output.

The trial evidence

The SPICE trial examined standardised hawthorn extract in patients with heart failure, published in the European Journal of Heart Failure. It is the largest and most cited hawthorn trial and looked at clinical outcome endpoints.

Earlier and smaller trials had examined exercise tolerance and symptom measures in mild to moderate heart failure, generally with modest positive findings on those endpoints.

As with CoQ10, the important caveat is population. The evidence base sits in patients with established cardiac dysfunction. Extrapolating to healthy adults with normal function is not supported by the same data, and we would rather note that than let the trial citation do more work than it should.

Why standardisation is not a technicality

Two hawthorn products naming the same plant can differ enormously in active constituent content, depending on plant part used, growing conditions, extraction solvent and extract ratio.

The trials used standardised extracts with defined procyanidin content. A product listing hawthorn with no standardisation and no extract ratio is effectively unquantified, and results from standardised-extract trials do not transfer to it.

When evaluating any hawthorn product, this is the specific thing to look for.

The interactions, which are real

Hawthorn has some of the more significant interactions among cardiovascular botanicals, and they are not theoretical.

Digoxin. Hawthorn may potentiate digoxin's effects. Digoxin has a narrow therapeutic index, meaning the gap between effective and toxic is small. This combination requires medical supervision.

Beta blockers, calcium channel blockers, antihypertensives. Additive effects on blood pressure and heart rate.

Nitrates. Additive vasodilation with hypotension risk.

PDE5 inhibitors. Same concern.

If you take any cardiac medication, hawthorn is a conversation to have with your prescriber before starting, not after.

Timeline

Hawthorn is slow. Trials examining symptom and exercise endpoints generally ran for weeks to months, and clinical guidance around it has historically suggested six to eight weeks before assessing response.

Anyone expecting acute effect is expecting the wrong thing from this ingredient.